KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Operations: 2018-2024

Historic Cash from Operations for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $64.9 million.

  • Castle Biosciences' Cash from Operations fell 3.03% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year increase of 4.56%. This contributed to the annual value of $64.9 million for FY2024, which is 1252.97% up from last year.
  • As of FY2024, Castle Biosciences' Cash from Operations stood at $64.9 million, which was up 1,252.97% from -$5.6 million recorded in FY2023.
  • Castle Biosciences' Cash from Operations' 5-year high stood at $64.9 million during FY2024, with a 5-year trough of -$41.7 million in FY2022.
  • In the last 3 years, Castle Biosciences' Cash from Operations had a median value of -$5.6 million in 2023 and averaged $5.9 million.
  • As far as peak fluctuations go, Castle Biosciences' Cash from Operations slumped by 292.43% in 2021, and later soared by 1,252.97% in 2024.
  • Yearly analysis of 5 years shows Castle Biosciences' Cash from Operations stood at $9.9 million in 2020, then crashed by 292.43% to -$19.0 million in 2021, then crashed by 119.43% to -$41.7 million in 2022, then surged by 86.49% to -$5.6 million in 2023, then skyrocketed by 1,252.97% to $64.9 million in 2024.